CATALYST DOSSIER · UPDATED 2026-11-05
$PCRX
biotech · convergence 5 · conviction WATCH
Price & Live Quote Loading live quote & chart…
Practice trade tools Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $PCRX?
Quantitative
Net Income (CY2026Q2) : $4.7M (+196.0% YoY)
Catalysts
Multi-spoke convergence : 10 convergent signals fired: merger, earnings, sc13d, xbrl_ni, edgar_phrases
Risks
Position-sizing discipline : Conviction WATCH (5 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Deal break risk : Antitrust/regulatory review or counterparty pullout would unwind the spread
Earnings binary : Print-day moves can swing ±15% — gap risk both directions
Sympathy basket (cerebro)
APP via tech r=+0.81 sympathetic (score 19)
STEM via tech r=+0.81 sympathetic (score 19)
LBTYA via comms r=+0.62 sympathetic (score 16)
CHTR via comms r=+0.62 sympathetic (score 7)
Signals Firing
merger earnings sc13d xbrl_ni edgar_phrases tender audit_extras auto_macro_adp_payrolls auto_macro_durable_goods auto_macro_fx_rates
Pick Track Record Date List Next-day max run Next-day close Hit +2%? 2026-11-03 sec_top_gappers +0.2% +0.0% — 2026-11-03 sec_top_moat_emerging +0.2% +0.0% — 2026-11-02 sec_top_gappers +0.0% -0.0% — 2026-11-02 sec_top_moat_emerging +0.0% -0.0% — 2026-10-30 sec_top_gappers +0.1% +0.0% — 2026-10-30 sec_top_moat_emerging +0.1% +0.0% — 2026-10-12 sec_top_gappers +0.0% -0.1% — 2026-10-12 sec_top_moat_emerging +0.0% -0.1% — 2026-10-08 sec_top_gappers -0.1% -0.2% — 2026-10-08 sec_top_moat_emerging -0.1% -0.2% —
Lifetime: 0/10 wins · hit-rate 0.0% on +2% intraday
Sympathy Basket APP via tech · score 19 STEM via tech · score 19 LBTYA via comms · score 16 CHTR via comms · score 7
Earnings Catalyst No recent earnings event.
Generate full earnings report
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks
and its losses — see the
trust report and
methodology .
Not financial advice. Confirm independently before trading.